| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |